TFF Pharmaceuticals Inc. (TFFP) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold—if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 4:00 PM EDTPivotal Trials to Begin in 2H-2021 for Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis (IPA) and Tacrolimus Inhalation Powder for Immunosuppression in Solid Organ Transplantation
Patent Filed for Once-a-Day Dosing for Tacrolimus Inhalation Powder, Achieving Therapeutic Blood Levels with a Single Low Dose
Science Day to be Held in June to Highlight Thin Film Freezing Platform Technology
Conference Call and Live Webcast Scheduled Today, Thursday, May 13, 2021, at 4:30pm EDT
AUSTIN, Texas--(BUSINESS WIRE)-- TFF Pharmaceuticals, Inc. (NASDAQ:... More
